Annovis Bio Balance Sheet Health
Financial Health criteria checks 4/6
Annovis Bio has a total shareholder equity of $7.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $14.4M and $7.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$12.64m |
| Equity | US$7.06m |
| Total liabilities | US$7.30m |
| Total assets | US$14.36m |
Recent financial health updates
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Recent updates
Annovis Bio To Continue Alzheimer's Disease Clinical Trials
Oct 17Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Sep 27Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Financial Position Analysis
Short Term Liabilities: ANVS's short term assets ($14.4M) exceed its short term liabilities ($5.4M).
Long Term Liabilities: ANVS's short term assets ($14.4M) exceed its long term liabilities ($1.9M).
Debt to Equity History and Analysis
Debt Level: ANVS is debt free.
Reducing Debt: ANVS currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANVS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ANVS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 50.5% each year